Table 4.
Time on treatment (months) of L1 treatment using Kaplan–Meier analysis, for the incident study cohort (patients with the start of any major depressive disorder episode within the study period, 1/1/2016–31/5/2018), n = 2553
| L1 treatment | TRD | N | Number (%) discontinued | Median time on treatment (95% CI), months | % on treatment at 3 months | % on treatment at 6 months | % on treatment at 12 months | Log rank P value |
|---|---|---|---|---|---|---|---|---|
| SSRI monotherapy | No TRD | 911 | 884 (97.04%) | 7.27 (6.08, 8.61) | 65.2% | 53.4% | 25.7% | < 0.0001 |
| TRD | 268 | 268 (100.00%) | 2.04 (1.87, 2.27) | 22.0% | 4.5% | 0.0% | ||
| Total | 1179 | 1152 (97.71%) | 3.78 (3.32, 4.67) | 55.3% | 42.2% | 19.8% | ||
| Other monotherapy | No TRD | 573 | 554 (96.68%) | 5.23 (4.24, 7.1) | 60.4% | 48.2% | 27.2% | < 0.0001 |
| TRD | 177 | 177 (100.00%) | 2.07 (1.91, 2.33) | 28.3% | 7.9% | 0.0% | ||
| Total | 750 | 731 (97.47%) | 3.22 (2.96, 3.95) | 52.8% | 38.7% | 20.8% | ||
| Combination therapy | No TRD | 393 | 376 (95.67%) | 9.50 (7.63, 10.65) | 70.2% | 58.7% | 31.6% | < 0.0001 |
| TRD | 156 | 156 (100.00%) | 2.32 (2.01, 2.63) | 30.1% | 6.4% | 0.0% | ||
| Total | 549 | 532 (96.90%) | 4.11 (3.48, 5.26) | 58.8% | 43.8% | 22.6% | ||
| TCA monotherapy | No TRD | 52 | 52 (100.00%) | 2.25 (0.99, 8.12) | 42.3% | 36.5% | 21.2% | 0.013 |
| TRD | 23 | 23 (100.00%) | 1.91 (1.18, 3.48) | 30.4% | 4.4% | 0.0% | ||
| Total | 75 | 75 (100.00%) | 2.17 (1.05, 3.32) | 38.7% | 26.7% | 14.7% | ||
| Overall | No TRD | 1929 | 1866 (96.73%) | 6.97 (6.12, 8.19) | 64.1% | 52.5% | 27.2% | < 0.0001 |
| TRD | 624 | 624 (100.00%) | 2.07 (1.97, 2.27) | 26.1% | 5.9% | 0.0% | ||
| Total | 2553 | 2490 (97.53%) | 3.65 (3.29, 3.98) | 54.8% | 41.1% | 20.5% |
(Other monotherapy comprised: 39.1% venlafaxine, 21.5% duloxetine, 10.1% vortioxetine, 9.2% bupropion, 8.4% mirtazapine, 3.9% milnacipran)
TRD treatment resistant depression, SSRI selective serotonin reuptake inhibitors, TCA tricyclic antidepressants